WARNING: members of the public are being contacted by people claiming to work for AXA Investment Managers UK Limited.  Find out more information and what to do by clicking here.

Investment Institute
Annual Outlook

China outlook – A bumpy path to reopening


Key points

  • China’s economic outlook continues to hinge on the path of the pandemic and Beijing’s response
  • We expect the authorities to pave the way for a reopening, but that path will be bumpy and uncertain
  • Falling exports – partially offset by a less bad property market – call for continued policy accommodation

COVID-19 response fails to keep up with virus

Three years into the COVID-19 pandemic, while most countries have exited emergency responses, China remains wedded to a rigid containment strategy. 2022 was a particularly difficult year for the Chinese economy, with the impact of rolling lockdowns exacerbated by a collapsing housing market and stiffening external headwinds – manifested in rising food and energy prices, escalating geopolitical tensions, and tightening global financial conditions. Beijing has tried to mitigate these shocks by easing counter-cyclical policies and finetuning its COVID-19 response after the Shanghai debacle. But those moves have failed to prevent a steep decline of economic growth. With annual GDP gains expected to more than halve to about 3% from 8.1% in 2021, Beijing is set to miss its growth target for the second time in three years.

The outlook for the economy will continue to hinge on the evolution of the pandemic and Beijing’s response. Continuing with draconian controls against repeated COVID-19 flare-ups will likely prolong the economic stress, creating permanent scarring in the economy and society. The housing market remains a wild card, as it struggles to find a bottom against depleting home-buyers’ confidence and acute financial stress among property developers. Exports – once a strong engine of growth – have also started to sputter and will likely lose further steam as developed economies fall into recession. These challenges will complicate Beijing’s counter-cyclical policies and make next year’s outlook more uncertain than usual. Below, we explain in detail these four drivers of the economy and the risks to our assessment.

Changing tack to reprioritise the economy

Starting with the pandemic, developments over the past year have likely brought two revelations to Beijing. First, the virus is unlikely to disappear any time soon, and could continue to mutate turning the pandemic to endemic, which may already be the case outside China. Second, and related, the medical response has to adapt for a long fight against a constantly changing enemy. The brutal lockdown in Shanghai, which brought China’s largest city to a standstill, was a painful lesson that achieving zero infections against a highly transmissible virus will inflict tremendous economic and social costs (Exhibit 11). Calls for an exit from the Zero COVID Policy (ZCP) have since grown as China becomes isolated from the rest of the world.

Economy at the mercy of the pandemic
Source: CEIC, Goldman Sachs and AXA IM Research, 16 November 2022

Beijing’s reluctance to change is likely a result of three considerations. Medically, China is not ready to exit the ZCP with a low immunity rate among its vast population and limited medical resources, which could prove insufficient to deal with increased severe cases upon reopening. Economically, the ZCP had been seen as a success not long ago for contributing to China’s growth outperformance and gains of export market share before this year. Finally, altering a policy, extolled as an emblem of China’s superior governing system ahead of a once-in-a-decade leadership reshuffle, was seen as unwise politically.

These arguments, however, have been weakened by recent events. The economic calculation has clearly shifted, reflected by the higher costs of tackling Omicron compared to the Alpha or Delta variants. Meanwhile, the conclusion of the 20th Party Congress has helped remove a major political uncertainty and refocus the party’s attention on its core objective of delivering growth and prosperity. The remaining hurdle is weak medical defences. Hence, moves to build such a defence should be seen as preparation for an exit from the ZCP.

Our baseline view for 2023 rests crucially on the assumption that the ZCP will be adjusted for an eventual reopening of the economy. We see this proceeding in three phases. Phase one focuses on getting the public medically and mentally ready for a change. This involves raising the vaccination rate (particularly for the elderly), introducing antiviral drugs, constructing more field hospitals, and reshaping public consensus to ease people’s fears of the virus. These changes are already underway and the latest announcement from Beijing of 20 measures to fine-tune the COVID-19 strategy suggests more is to come. Phase two puts the emphasis on reopening the domestic economy by easing social and mobility restrictions, reducing mass testing, and abandoning the frequent use of ‘static management’. A broad liberalisation within China is assumed to be reached by the middle of next year. The final step is to open the border with the rest of the world through successive reductions of quarantine restrictions for visitors.

It is important to reiterate our long-held view that no official announcement on ending the ZCP will be given until, perhaps, full liberalisation is achieved. But under the ZCP banner, we see the emphasis shifting from achieving zero infections at all costs to ‘dynamically adjusting’ the strategy to reprioritise economic normalisation. Investors therefore need to pay more attention to what Beijing does than what it says.

There is however considerable uncertainty around this baseline view. It is entirely possible that the fear of exposing China’s vast unvaccinated population to a virulent virus continues to hold Beijing back from reopening. And even if the ZCP is adjusted, the path could be bumpier than hoped. Too slow a change will do little to save the economy, while too fast an exit could lead to surging infections and hospitalisations that overwhelm the public health system. The ensuing social backlash could set back the reopening and economic recovery. We have built a cautious forecast – including a negative quarter of growth followed by only a partial recovery – to account for potential hiccups in this transition, but the actual path ahead could be bumpier still.

Property and exports switch sides

Besides the pandemic, the ongoing property market turmoil has also rattled the economy and financial markets. Fears of contagion to the household sector and banking system – following the mortgage boycott instance – prompted the authorities to ease property policies. But this was barely enough to slow the deterioration of conditions. The good news is that the policy wind has shifted further with Beijing now taking more substantial steps to ease developers’ funding stress. The bad news is that there are no easy fixes to the structural imbalances, with an overhang of housing supply in lower-tier cities and excess leverage at many private-sector developers. After abruptly pricking the bubble, Beijing now must manage its fallout. We expect further policy support to stabilise the market next year, helped by easing COVID-19 controls. But there will unlikely be a vigorous rebound of activities until structural challenges are tackled.

The external sector is set to become less supportive of the economy next year. After acting as a solid engine of growth since 2020, export activity has faltered lately and is expected to contract as developed economies slide into recession. In addition, rising geopolitical tensions between China and the US – notably in the area of advanced technology – could further impact an already soured trade relationship. The loss of this export growth contribution could add to the urgency for Beijing to ease COVID-19 controls to revive domestic demand.

Better transmission improves policy efficacy

The multitude of economic headwinds call for continued accommodation from China’s counter-cyclical policies. Compared to this year, policy efficacy may improve in 2023 if easing COVID-19 controls and stabilising property market can help to unclog policy transmission channels. On the monetary side, the room for aggressive easing is limited by concerns about currency depreciation and capital outflows, while tightening is unlikely given the uncertain path of the economy. Incremental policy exit is possible later in the year only if economic reopening proceeds smoothly. Fiscal policy will likely stay supportive too, but Beijing may struggle to repeat some ad-hoc, frontloaded, stimulus implemented this year given the already stretched fiscal balance sheets of local governments. With reduced potential for conventional stimulus, there are few options left to bolster growth other than freeing the economy from the grip of the pandemic.

Dissecting our growth forecast for 2023-2024
Source: CEIC and AXA IM Research, 16 November 2022

Exhibit 12 shows how our above-consensus 5% growth forecast for 2023 is derived. This is followed by a slight moderation to 4.8% in 2024 as the economy reverts to trend. The biggest swing factor in our forecast is the ZCP, which offers a two-sided risk. However, we consider the chances of inaction, or delayed action, from the authorities as greater than proactive action. In an adverse scenario of China continuing its current pandemic response for another year, we think the economy would suffer from deeper economic scarring and further reduced space for counter-cyclical policy. Annual growth could fall to 3.5% or lower in that scenario even with the help of a low base.

Our views for 2023

Read our full outlook to find out more about our experts' views.

Full report: Outlook 2023
Download report (1.42 MB)
Investment Institute

2023 Outlook

Our experts share their views for the year ahead.

Find out more

    Disclaimer

    This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

    It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date.

    All information in this document is established on data made public by official providers of economic and market statistics. AXA Investment Managers disclaims any and all liability relating to a decision based on or for reliance on this document. All exhibits included in this document, unless stated otherwise, are as of the publication date of this document.

    Furthermore, due to the subjective nature of these opinions and analysis, these data, projections, forecasts, anticipations, hypothesis, etc. are not necessary used or followed by AXA IM’s portfolio management teams or its affiliates, who may act based on their own opinions. Any reproduction of this information, in whole or in part is, unless otherwise authorised by AXA IM, prohibited.

    Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI’s express written consent.

    Risk Warning

    The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested.